NMTC trades 2.9% above Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NMTC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, NeuroOne Medical Technologies Corporation (NMTC) has a Wall Street consensus price target of $3.00, based on estimates from 2 covering analysts. With the stock currently trading at $3.09, this represents a potential downside of -2.9%. The company has a market capitalization of $27M.
Analyst price targets range from a low of $3.00 to a high of $3.00, representing a 0% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NMTC trades at a trailing P/E of -5.7x. Analysts expect EPS to grow +84.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LIVNLivaNova PLC | $4.6B | $83.58 | $81.43 | -2.6% | Buy | 19.7x | 15 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
ITRIItron, Inc. | $3.7B | $84.44 | $136.80 | +62.0% | Hold | 14.1x | 37 |
ANIKAnika Therapeutics, Inc. | $213M | $15.87 | — | — | Buy | — | 6 |
MLABMesa Laboratories, Inc. | $531M | $96.16 | $94.00 | -2.2% | Hold | 10.6x | 8 |
ATECAlphatec Holdings, Inc. | $1.4B | $9.38 | $18.00 | +91.9% | Buy | 29.3x | 18 |
Quick answers to the most common questions about buying NMTC stock.
Wall Street's consensus price target for NMTC is $3, -2.9% from its current price of $3.09. The below-market target from 2 analysts suggests limited near-term appreciation.
NMTC has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $3 implies -2.9% downside from current levels.
NMTC's current price is $3.09 with a consensus target of $3 (-2.9% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $3 for NMTC, while the most conservative target is $3. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
NMTC is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NMTC stock forecast based on 2 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $3 (bear case) to $3 (bull case). The median consensus rating is "Buy".
Analysts are cautious on NMTC, with 0 Sell ratings and a price target of $3 (-2.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NMTC analyst price targets range from $3 to $3, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.